ArticleBritish journal of haematology2026
Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This prospective study evaluated the incidence and dynamics of frailty in 156 adults with lymphoproliferative syndromes undergoing autologous haematopoietic stem cell transplantation (HSCT). Frailty was assessed using the haematopoietic cell transplantation (HCT) frailty scale in patients from 15 Spanish institutions at initial consultation, transplant admission and day +100. Quality of life (QoL) was measured using the EuroQoL. At first consultation, 45 patients (28.8%) were classified as fit, 93 (59.6%) as pre-frail and 18 (11.6%) as frail. Frailty was more frequent among older patients, those with Karnofsky performance status (KPS) below 90%, and abnormal Mini-Cog scores (<3). Rates of relapse, death, readmission and median hospital stay were similar across frailty groups. However, frail patients reported significantly worse QoL. One-year non-relapse mortality was higher in frail patients than in pre-frail and fit patients, although differences were not statistically significant (p = 0.19). At day +100, 33.6% of patients were fit, 57.9% pre-frail and 8.5% frail, demonstrating significant transitions in frailty over time (p = 0.001). Moreover, frail patients showed lower relapse-free [53.3% (17.7-79.6) vs. 85.3% (68.3-93.6), p = 0.05] and overall survival [77.8% (36.5-93.9) vs. 100%, p = 0.16], and worse perceived QoL than fit ones. Overall, frailty was dynamic and clinically relevant, supporting routine assessment and targeted interventions to mitigate adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.